Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Nuvation Bio Completes Acquisition of AnHeart Therapeutics [Yahoo! Finance]
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate [Seeking Alpha]